Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 24, 2026.

Factors Contributing to the Evolution of mecA-Mediated β-lactam Resistance in Staphylococci: Update and New Insights From Whole Genome Sequencing (WGS)

Maria Miragaia

Frontiers in Microbiology · 2018 · Review

doi:10.3389/fmicb.2018.02723

Abstract

The understanding of the mechanisms of antibiotic resistance development are fundamental to alert and preview beforehand, the large scale dissemination of resistance to antibiotics, enabling the design of strategies to prevent its spread. Resistance to broad-spectrum β-lactams is globally spread in staphylococci including hospitals, farms and community environments, turning ineffective the most widely used and efficient class of antibiotics to treat staphylococcal infections. The use of next-generation sequencing (NGS) technologies at a bacterial population level provided a considerable progress in the identification of key steps that led to β-lactam resistance development and dissemination. Data obtained from multiple studies indicated that β-lactam resistance developed from a harmless core gene (mecA1) encoding a penicillin-binding protein (PbpD) from staphylococcal species of animal origin (S. sciuri group) due to extensive beta-lactams use in human created environments. Emergence of the resistance determinant involved distortion of PbpD active site, increase in mecA1 expression, addition of regulators (mecR1, mecI) and integration into a mobile genetic element (SCCmec). SCCmec was then transferred into species of coagulase-negative staphylococci (CoNS) that are able to colonize both animals and humans and subsequently transferred to S. aureus of human origin. Adaptation of S. aureus to the exogenously acquired SCCmec involved, deletion and mutation of genes implicated in general metabolism (auxiliary genes) and general stress response and the adjustment of metabolic networks, what was accompanied by an increase in β-lactams minimal inhibitory concentration and the transition from a heterogeneous to homogeneous resistance profile. Nowadays, methicillin-resistant S. aureus (MRSA) carrying SCCmec constitutes one of the most important worldwide pandemics. The stages of resistance development described for β-lactams may serve as a model for previewing and preventing the emergence of resistance to other classes of antibiotics.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Antimicrobial resistance threatens the effective prevention and treatment strategies of an increasing range of bacterial infections. In 21st century we are facing the real possibility that minor injuries and common infections can lead to death. A detailed understanding of the evolutionary processes occurring in nature that lead to resistance development is thus essential for anticipating its emergence and to restrain its spread.

One of the best models of resistance development is the emergence of methicillin resistance in staphylococci not only due the fact that it is extremely well documented, but mainly because it gave rise to methicillin-resistant Staphylococcus aureus (MRSA) pandemics – presently a major public health concern.

Due to their high efficacy and low toxicity, β-lactams are the most widely used class of antibiotics. They inhibit bacterial cell wall biosynthesis through irreversible binding to the traspeptidase domain of penicillin-binding proteins (PBPs).

Staphylococcus species have a broad distribution in nature and consist of large populations. They are common commensals of the skin and mucous membranes of humans and animals and are ubiquitously recovered from the environment. Although during most of its existence they live as mere colonizers, when the skin and mucous membranes barrier of their host is impaired and the host is immunocompromized staphylococci may arise as important pathogens. Among all staphylococcal species, S. aureus, is considered to be the most pathogenic, being associated to a myriad of infections ranging from mild skin infections to life-threatening diseases.

The major driving force for the emergence of β-lactams resistance in staphylococci was the continuous exposure to β-lactams in multiple environments: in soils where they had to co-exist with penicillin-producing fungi; in production animal farms wherein large amounts of β-lactam antibiotics were used as food additives, and during treatment of bacterial infections.

All MRSA contain a copy of an exogenous mec gene that codifies for PBPs with low affinity for β-lactams (mecA, mecB, mecC, and mecD), In this review we will focus on the evolution and emergence of methicillin resistance mediated by mecA which encodes an extra PBP, PBP2A with a low binding affinity to virtually all β-lactams. In the presence of β-lactams antibiotics the transpeptidase domain of all native PBPs is inactivated, but bacteria containing mecA continue to synthesize cell wall as a result of the cooperation between transpeptidase domain of the PBP2A and the transglycosylase domain of the native staphylococcal PBP2. The few β-lactam to which mecA does not confer resistance include ceftobiprole and ceftaroline which are active against MRSA and penicillin G, ampicillin and amoxicillin which are active against penicillinase-negative MRSA strains (a minority, nowadays).

Several efforts have been made to clarify the origin of mecA-mediated resistance to β-lactams in staphylococci and the use of state-of-the-art WGS technology has provided unprecedented advances (see Table 1). Nevertheless, the precise steps that led to β-lactam resistance development and dissemination are still not totally clear and are a matter of speculation.

History of β-Lactams and β-Lactam Resistance

Penicillin, a natural antibacterial compound produced by fungi, was first discovered in 1928 by Alexander Fleming. However, due to low production yield, instability of the compound and problems in purification it was only later, in 1941, that penicillin was used as an antibiotic to treat human bacterial infections. The necessity to treat sick and wounded soldiers in the Second World War promoted the mass production of penicillin, and in 1945 this antibiotic was already used routinely in human clinical practice.

Based on studies showing that penicillin is a growth promoter of chickens, pigs and livestock, in 1951, the Food and Drug Administration (FDA) also approved the use of penicillin in animals. Nowadays, penicillin and other β-lactams continue to be used in many countries in food production animals not only to enhance animal growth, but also to treat infections and as a prophylactic. In fact, recent surveillance studies in Europe indicate that 25% of all antibiotic consumption (in mg/PCU) in veterinary setting relate to penicillin, much of which are used for non-therapeutic purposes in chickens, cattle, and swine, compared with just a small quantity used for clinical treatments.

A natural consequence of penicillin exposure was the development of antibiotic resistance. In fact, in 1942, only 2 years after the introduction of penicillin into clinical practice, the first penicillin-resistant S. aureus emerged in a hospital and shortly after (1960s) were also disseminated in the community, reaching around 80%. Penicillin resistance emerged due to the acquisition of β-lactamases that were able to hydrolyze and inactivate penicillin. Further developments to overcome resistance to penicillin included the synthesis of penicillinase-resistant penicillins, such as methicillin in 1960. However, due to its amazing adaptative power, S. aureus that were resistant to methicillin and to all β-lactams emerged right after its first use in the treatment of bacterial infections, through the acquisition of mecA. This event has lead to the emergence of methicillin-resistant S. aureus (MRSA) strains and to one of the most important bacterial pandemics in hospitals worldwide. The MRSA rates in hospitals increased then, exponentially, reaching extremely high levels (above 60%) in the 1990s, mainly in Southern European countries. Similar to what was observed before for penicillin, this was followed by a wave of MRSA emergence in the community, causing infections in otherwise healthy persons. Community-associated MRSA (CA-MRSA) are nowadays endemic in the community in specific countries like United States and here they have also become major multidrug resistant hospital clones. Additionally, resistance to β-lactams has expanded into farm environments wherein specific MRSA clones, like ST398 have become frequent colonizers of production animals and of humans in contact with them.

As was observed for β-lactams, the emergence of drug resistance has been described following the introduction of each new antimicrobial class. The recent awareness by political authorities of the problem of antimicrobial resistance has lead to actions toward the banning of antimicrobial use in animals. However, rules controlling antimicrobial use in animals have been applied mainly in Europe, and still some of the antimicrobials, like penicillins, used to treat human disease continue to be heavily used in animals in European countries.

The Structural Element of β-Lactam Resistance: the mecA Gene

β-lactams target the PBPs, involved in the synthesis of peptidoglycan, the major structural component of the bacterial cell wall. In particular, PBPs catalyze the main reactions involved in the polymerization of peptidoglycan, namely the elongation of glycan strands (transglycosilation) and the cross-linking between stem peptides of different glycan strands (transpeptidation). Binding of β-lactams to native PBPs turns them inactive, what prevents peptidoglycan synthesis and bacterial growth. This reaction involves the break of the β-lactam ring amide bond and acylation of the PBPs, which gives rise to a serine ester-linked acyl derivative that is extremely stable and has a low rate of deacylation.

The mecA gene encodes a high-molecular weight class B PBP, called PBP2A, which contains two domains, the C-terminal domain which is known to have a transpeptidation function, and a N-terminal domain to which no function has been attributed, the so called non-binding (NB) domain. Resistance is provided by the fact that this extra PBP has a lower efficiency of acylation by β-lactams, which is believed to result from a lower affinity for these compounds and from a slow rate of acylation. Resolution of PBP2A crystal structure showed that the poor acylation rate observed is due to the presence of a distorted active site, provided by a higher flexibility of the NB domain and by differences in regions close to the active site groove in the transpeptidase domain. Furthermore, the position of Ser403 was considered crucial for the effective nucleophilic attack of the β-lactam ring, which leads to acylation of the protein.

The Mobile Element Carrying mecA: SCCmec

The mecA gene is carried in a mobile genetic element called staphylococcal cassette chromosome mec (SCCmec). SCCmec is delimited by distinctive terminal inverted and direct repeats formed upon SCCmec insertion (DR-left downstream orfX, attL; DR-right at SCCmec end, attR) in a single chromosomal location, in the 3′ end of orfX, a RNA methyltransferase that is localized near the origin of replication. This mobile genetic element is composed of two central elements, the mec complex containing mecA and intact and deleted forms of its regulators (mecI, mecR1) and the ccr complex composed of cassette chromosme recombinases (ccr) involved in its mobility. The remaining portions of SCCmec, are composed of non-essential components, namely additional metal and antibiotic resistance genes carried by transposons and plasmids, as well as genes of unknown function, which are named J regions. The J3 region is located between orfX and mec complex, the J2 region is flanked by mec complex and the ccr complex and the J1 region between ccr complex and the right extremity of the element (see Figure 1). More recently, mecR2, coding for an anti-repressor of mecA was described to exist downstream mecI, which together with mecI and mecR1 constitute an unusual three-component arrangement. So far as many as thirteen different structural types of SCCmec have been described in S. aureus1 that range between 20 and 70 Kb. The different types of SCCmec correspond to different combinations of mec complex class (A-E), according to the presence/absence of regulatory genes and insertion sequences, and ccr allotypes (ccrAB and ccrC).

SCCmec is believed to have been acquired a limited number of times in S. aureus, but acquisition of this element appears to provide a major advantage to bacteria mainly in the hospital environment. In fact, the acquisition of different types of SCCmec by methicillin-susceptible S. aureus (MSSA) of diverse genetic backgrounds gave rise to several MRSA pandemics over time, namely the Iberian (ST247-I), Brazilian (ST239-III), New York-Japan (ST5-II), EMRSA16 (ST36-II), EMRSA15 (ST22-IV), Berlin (ST45-IV), United States 300 (ST8-IV), and ST398-V. In contrast to S. aureus, in coagulase-negative staphylococci (CoNS), there is not a clear association between SCCmec and specific genetic backgrounds. However, it is still not clear if this derives from the fact that SCCmec was acquired a higher number of times or from a higher instability of SCCmec structure in these species. Nevertheless, specific SCCmec types appear to be more common to certain CoNS species. SCCmec type I and VI are more common in Staphylococcus hominis, SCCmec III in Staphylococcus sciuri group of species, SCCmec IV in S. epidermidis, and SCCmec V in S. haemolyticus.

The true breadth of genetic diversity of SCCmec elements is still unknown. While in S. aureus this structure has been shown to be relatively stable, in CoNS, such as S. epidermidis and S. haemolyticus, a high genetic diversity has been described. This might be due to the fact that CoNS species have a high recombination rate, an enhanced ability to acquire and maintain exogenous genetic material or because these elements have been acquired earlier by these species than by S. aureus. In the era of WGS where detailed information on the entire genomes of thousands of staphylococci are being gathered, the number of types and subtypes of SCCmec have increased exponentially1, and this challenges the traditional criteria and methodologies that were previously defined to classify SCCmec types, mainly based on PCR. A web-tool, SCCmecFinder, able to identify all SCCmec element types (I to XIII) and SCCmec IV and V subtypes was recently developed to classify SCCmec types based on WGS data. The characterization of the SCCmec elements is based on two different gene prediction approaches to achieve correct annotation.

The SCC Elements

Although due to its clinical relevance, SCCmec is the most popular element, several other SCC elements not carrying the mec complex (SCC) or either mec complex and ccr complex (pseudo-SCC) have been identified at the orfX site. These elements can carry diverse genes relevant for staphylococcal survival and virulence, namely conferring heavy metal resistance genes providing capsule production, cell-wall biosynthesis, restriction/modification functions or immune protection. These elements can be found alone in the chromosome or in tandem with SCCmec or other SCC elements, being in this case named composite islands (CI). Examples of such CIs include the SCCmec III-SCCmer from the pandemic MRSA Brazilian clone and the SCCmec IV-ACME from the USA300 CA-MRSA clone. Although many studies have described the structure and contents of these elements, few studies have addressed their true contribution for staphylococcal virulence or fitness.

Besides being inserted at the exact same location as SCCmec, SCC and pseudo-SCC elements have been described to have regions of homology with SCCmec (see Table 2), suggesting that their evolutionary history is related. Still, until recently the nature of their relatedness remained elusive.

Transfer of SCC Elements

SCCmec with exactly the same nucleotide sequence were found in different staphylococcal strains and species, suggesting that this element is frequently transferred among staphylococci. However, the mechanisms of SCC and SCCmec insertion and excision from the chromosome as well as the mechanism of transfer is still elusive and it is likely that several different mechanisms are involved.

When grown in antibiotic free medium SCCmec can be excised from the chromosome, a reaction catalyzed by the cassette chromosome recombinases (Ccr). Immediately after excision, SCCmec circularizes into an extrachromosomal intermediate form and the attSCC sites are created in the chromosome (attB) and the intermediate circular form (attS). The created attSCC sites, work like recognition sites for the Ccr enzymes for a later integration into the chromosome. During SCCmec excision and insertion orfX remains always intact.

Electrophoretic mobility shift assay (EMSA) showed that Ccr enzymes recognize a minimum of 14-bp sequence in the terminal sequence of the orfX that contains always the conserved sequence (TATCATAA), which is also found in SCCmec (attS). However, DNA sequences flanking the att sites were shown to also have a role on the frequency and efficiency of SCCmec insertion. This sequence specificity was thus probably important in the epidemiology of SCCmec acquisition by staphylococci and might partly explain the association of some SCCmec to specific genetic backgrounds or staphylococcal species.

According to studies of translational fusions of the ccr promoter with green fluorescent protein the ccr activity and associated SCCmec excision is a bistable process occurring only in a small fraction of cells within the population. The fate of the extrachromosomal circularized SCC elements after they are formed is still a mystery. SCC elements have once been regarded as non-replicative, due to the absence of a replication origin, but recent crystallographic studies have provided evidence that SCCmec elements encode an active MCM-like helicase, suggesting that they can eventually replicate in the cytoplasm before being transferred, but further studies are needed to confirm these observations.

The transfer of SCCmec have been successfully achieved in the laboratory by several different genetic mechanisms. In particular susceptible strains in contact with phage lysates containing this mobile genetic element were shown to become resistant to β-lactams and SCCmec elements were successfully packaged into bacteriophage capsides. Additionally, transfer of SCCmec was also achieved through natural transformation, upon induction of SigH in very specific laboratory growth conditions. Moreover, a chromosomally encoded and laboratory-constructed derivative of SCCmec was captured on a conjugative plasmid and transferred by filter-mating into different S. aureus and S. epidermidis recipients. Also, evidence of possible transfer of SCCmec by conjugation was the finding of a mecA homologue within a plasmid of Macrococcus caseolyticus, a species phylogenetically related to Staphylococcus.

In spite of the huge effort of the scientific community in elucidating the mechanism of SCCmec transfer, many of the studies described occurred in very artificial conditions and it remains to be clarified which mechanism(s) are actually more frequent in vivo.

The Origin of the Methicillin Resistance Determinant – mecA Evolution in S. sciuri Group

Early studies, based on structural nucleotide identity, have proposed that the mecA gene originated from recombination between a PBP from E. coli or from Enterococcus hirae with a β-lactamase encoding gene. A theory that was later supported by the finding by WGS of another mec allotype (mecC) as part of a class E mec complex, containing blaZ (mecI-mecR1-mecC-blaZ) in Macrococcus caseolyticus and S. xylosus.

Other lines of evidence suggest that mecA originated from native PBPs of species of the Staphylococcus sciuri group – a primordial phylogenetic clade, including S. sciuri, Staphylococcus fleurettii, Staphylococcus vitulinus, Staphylococcus lentus, and Staphylococcus stepanovicci, which most important ecological niches are the soil and skin and mucous membranes of wild and production animals.

The use of WGS on a large collection of isolates belonging to the S. sciuri group revealed the presence of homologues of S. aureus mecA with different levels of homology that were ubiquitous within some of the species (see Figure 2A). However, in contrast to mecA in S. aureus, mecA homologs in S. sciuri group species were all located approximately 200 Kb apart from orfX (native location) between mva and xyl operons, outside any SCC element (see Figure 2B). The results suggest that mecA has been transmitted vertically during the early stages of staphylococcal speciation (see Figure 2A; Step 1, Figure 3).

Although the primary function of these mecA precursors was probably related to cell wall synthesis and not to antimicrobial resistance, the complete evolution from a native PBP into a resistance determinant appears to have been a stepwise process that occurred within this group of species. S. sciuri carries the most ancestral form of mecA (mecA1) which has 85% homology in nucleotide sequence with S. aureus mecA; S. vitulinus harbors an intermediary form (mecA2) with 94% homology and all S. fleurettii and some S. vitulinus have a mecA form that is almost identical to that of S. aureus mecA (mecAf, mecAv; 99% homology) (see Figure 2 and Table 3). In S. lentus and S. stepanovicii so far no mecA homolog has been described,, but no extensive and detailed study was ever performed in these two species.

The only mecA homologue that confers resistance to β-lactams is the mecA in S. fleuretti. The same mecA homologue in S. vitulinus and the mecA1 and mecA2 found in S. sciuri and S. vitulinus, respectively, do not confer resistance to β-lactams in the great majority of strains. However, S. sciuri and S. vitulinus strains exhibiting β-lactam resistance have been reported. Recent work by wherein a large collection of S. sciuri and S. vitulinus were analyzed by WGS showed that β-lactam resistance in these species emerged multiple times during evolution and was driven mainly by the contact with human created environments, namely with the beginning of the use of antibiotics in production animals and humans. The mechanisms of resistance development in these two species included: (i) the structural diversification of the non-binding domain of native PBPs which altered the structure of the active site and exposure of ser403; (ii) mutations and insertion of IS256 in the promoters of mecA homologs that were associated to an increased expression of the proteins; (iii) acquisition of SCCmec. Additionally, like in S. aureus, the bacterial genetic background plays an important role in the expression of β-lactam resistance in the S. sciuri group of species, since the exact same gene allele was found associated to both susceptible and resistant strains.

Additional evidence supporting that S. sciuri mecA1 was the evolutionary precursor of S. aureus mecA, include the fact that this gene could be recruited to express methicillin resistance in S. sciuri after stepwise exposure to methicillin. Moreover, the activated copy of S. sciuri mecA1 was, similarly, able to restore methicillin resistance phenotype, when transduced into methicillin-susceptible S. aureus (MSSA), conferring high level, homogeneous and broad-spectrum β-lactam resistance. Furthermore, the S. sciuri mecA1 when transduced into MSSA was shown to act exactly like S. aureus mecA, being controlled by S. aureus mecA regulators (mecI and mecR1) and its product (PBP4) taking part in cell wall biosynthesis, producing a peptidoglycan typical of methicillin-resistant S. aureus.

Besides mecA, other mec genes have been identified that are associated with β-lactam resistance, namely mecB and mecD in Macrococcus caseolyticus and mecC in S. aureus, S. xylosus, S. sciuri carnaticus, and S. stepanovicii. The mecB and mecD are the most distant from S. aureus mecA, having, respectively, a nucleotide identity with mecA that is equal or lower than 62%, whereas mecC has 69% nucleotide sequence identity. All mec forms confer resistance to β-lactams to their natural hosts and their introduction into a susceptible S. aureus genetic background was able to provide a resistance phenotype, confirming that they should encode a PBP with low-affinity to β-lactams that participates in cell wall synthesis. Both mecB and mecC were carried within mobile genetic elements structurally similar to SCCmec that were inserted in the orfX region (SCCmec XI, SCCmec IX-like) and mecB was additionally found within a plasmid in M. caseolyticus. The mecD gene is carried within a resistance island (McRImecD-1, McRImecD-2) that is inserted in 3′ end of the rpsI gene. Besides mecD this island contains genes for an integrase of the tyrosine recombinase family, but does not resemble either SCC elements or mecB-carrying mobile genetic elements. However, none of the mecB, mecC or mecD was found within the native location (200 Kb apart from orfX).

The exact evolutionary link between mecA, mecB, mecC and mecD forms is still undetermined. Among all mec genes, mecA is apparently, the most successful in Staphylococcus. The mecB was recently found within a plasmid in a single S. aureus human carriage strain belonging to ST7 and mecC has been limited to only a few S. aureus clonal lineages (CC130 and ST425) and four Staphylococcus species (S. sciuri, S. xylosus, S. stepanovicci, and S. aureus). MRSA harboring mecC are believed to have a zoonotic origin and although they were reported in several different countries, they have been rarely observed in human infection. However, surveillance of dissemination of these mec genes should not be disregarded, since antibiotic use and the consequent selective pressure could drive fast evolutionary leaps that can lead to their precipitous spread.

Stages in the Evolution of SCCmec

Most of the efforts have been focused on the clarification of the origin and evolution of the β-lactam resistance determinant (mecA). Much less information is available regarding the evolution of SCCmec, the mobile element carrying mecA, which is responsible for the worldwide spreading of β-lactam resistance among staphylococci. SCCmec is a mosaic-like element that was described to contain multiple transposable elements, plasmids and insertion sequences in J regions, a genetic environment that per si can promote and facilitate genetic variation and recombination, what has been hindering the reliable tracing of their phylogeny.

The characterization of the native location of mecA homologs, the SCC insertion site and the genetic background of a large collection of isolates belonging to S. sciuri group by comparative genomics showed that SCC elements and mecA and flanking regions evolved in parallel in these species in these two distinct chromosomal locations.

Assembly of the mec Complex in the Native Location

The mecA homologs flanking genes in the native location were found to be the same as those flanking mecA inside SCCmec, encompassing the J2 and J3 regions (see Table 3). Moreover, as for native mecA homologs, the level of homology of their flanking genes (psm-mec and ugpQ) with the same genes in SCCmec from MRSA, varied according to the phylogeny, wherein those of S. fleuretti were the most similar and those of S. sciuri were the most distant. The results suggest that the first stage of SCCmec evolution included the evolution of mecA homologs and their neighbor genes in the native location (Step 1, Figure 3). This was followed by the creation of the mec complex (Step 2, Figure 3). The mecR2 was the first regulator to be added in S. sciuri at the native location near mecA1, since the most ancient precursor of mecR2 was found in this species. This gene organization was preserved along phylogeny and became ubiquitous in S. fleurettii and S. vitulinus. Addition of mecR1 and mecI happened later, after the evolution of the ancestral mecA1 into mecA was complete, as demonstrated by the lack of these regulators in S. sciuri and their occurrence in the native location of S. fleurettii and S. vitulinus near mecA. These finding came to reconcile previous controversies, suggesting that although mecA1 was the original precursor of mecA, S. fleuretti/S. vitulinus were probably the last donors of the mec complex to give rise to SCCmec. The addition of IS431 element probably occurred later, after mecA, regulators and neighboring regions were mobilized into a SCC element located in the orfX region (Step 3, Figure 3). Alternatively, it could have been added during their mobilization, as it was never detected in the native location in any of the strains tested.

Acquisition and expression of mecA in species in which this gene is not native imposes a fitness cost to bacteria. For this reason, the step of addition of regulators with subsequent mecA repression appears to have been particularly crucial in the maintenance of the gene in new host species and thus in mecA dissemination. In fact, some of the first methicillin resistant staphylococci, the so-called pre-MRSA (Step 9, Figure 3), contained intact regulators and a susceptible phenotype.

Studies wherein the mec complex region was characterized in MRSA and MR-CoNS revealed that although mecI and the 3′ end of mecR1 are deleted in a great proportion of contemporary clinical strains, the 5′ end portion of mecR1 as well as a copy of IS431 downstream mecA (IS431-R) are conserved in every strain. Moreover, deletion of mecI and mecR1 promoted by IS431 was accomplished in vitro upon selection with methicillin in a S. haemolyticus with a mec complex type A. These observations are in accordance with the view that the mec regulators and the IS431-R together with mecA were once the original components of the mec region DNA and that deletion of the regulators occurred at a later time in evolution (Step 7, Figure 3). On the other hand, the similarity of nucleotide sequence in regions located upstream of the mec complex in four different mec complex classes, suggests that deletion of the mec regulators must have occurred after the establishment of the prototypic mec complex A in a SCCmec element.

Thus the assembly of mec complex A seems to be the first step of genetic evolution, followed by its establishment in SCCmec and subsequent deletion of the regulators to originate the different mec complex classes (mec complex B, C, D, E).

SCC Element Evolution in the orfX Region

Analysis of the S. sciuri orfX region showed that SCC elements most probably originated in S. sciuri and were assembled from housekeeping genes located in this region (Step 4, Figure 3), as evidenced by the finding of the same housekeeping genes either outside or within SCC elements – a finding not observed in the other species of the S. sciuri group. Additionally, in S. sciuri the most ancestral forms of cassette chromosome recombinases (ccr) and the highest genetic diversity were found, including almost all ccr allotypes described in S. aureus. Interestingly, it was also in this species that a SCCmec type III-like was found with high homology simultaneously with the mec complex and J2 region of S. aureus SCCmec type III and the J1 region and an ancestral form of ccrAB3 of S. sciuri SCC non-mec (see Table 2). The results suggest that SCCmec III originated in S. sciuri, probably through the integration of the mec complex and J2 region from S. vitulinus/S. fleuretti into a resident SCC non-mec carrying ccrAB3 (Step 5, Figure 3). However, the mechanism that mobilized the mec complex from S. vitulinus/S. fleuretti to an SCC in S. sciuri is still not known. Once formed SCCmec III probably disseminated to other CoNS species, namely S. epidermidis and S. aureus ST239, wherein SCCmec III was found to be prevalent (Step 6, Figure 3).

Although it is apparent that the origin of SCCmec type III is S. sciuri, the source of the remaining SCCmec types elements remains unclear. In contrast to S. sciuri, which carried a high diversity of ccr allotypes, methicillin susceptible CoNS species belonging to more recent clades in the phylogeny of staphylococci, which include Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis, were particularly enriched in a specific allotype of ccr. The ccrAB2 was found to be common in S. epidermidis, ccrAB1 in S. hominis and ccrC in S. haemolyticus, which is coincidently the same type of ccr carried by the most frequent SCCmec in these species. It is thus tempting to speculate that each SCCmec type can result from the integration of mec complex, probably through recombination, into a resident SCC element in these species. This hypothesis is supported by the identification of SCC non-mec elements carrying different ccrAB types in S. aureus and CoNS with regions of high homology with known SCCmec types. However, the enrichment of certain SCCmec types in particular species may also derive from the described specificity of the different types of Ccr enzymes as described above.

SCCmec Diversification

The next stage of SCCmec evolution that is believed to be still ongoing includes the diversification and dissemination of the SCCmec element among the staphylococcal population (Step 7, Figure 3). The existence of similar regions among different SCCmec types, like the J1 region in SCCmec type II and IV or the mec complex B between SCCmec type I and IV suggest that the different SCCmec types are related.

The involvement in the diversification process of species, such as S. epidermidis, S. hominis and S. haemolyticus is apparent. Besides being reservoirs of specific types of SCCmec and ccr allotypes, these species harbor a huge number of non-described SCCmec types, evidencing their key role in the current diversification of SCCmec.

Moreover, factors associated to hospital environment appear to be driving the diversification and acquisition of SCCmec in species like S. epidermidis. One of the factors related to the clinical setting that might be triggering SCCmec diversification is the use of antibiotics, namely β-lactams and vancomycin, which were already shown to promote the expression of recombinases. The excision of SCC elements promoted by ccr overexpression may create new opportunities of recombination between different elements within the same strain, giving rise to new SCCmec structures.

The Importance of Genetic Background for the Acquisition of SCCmec and for the Expression of β-Lactam Resistance in S. aureus

The transfer of SCCmec from CoNS to S. aureus was probably a subsequent step (Step 8). Several lines of evidence suggest that acquisition and expression of mecA by S. aureus was a complex process involving multiple genetic and metabolic alterations. The construction of a Tn551 transposon library in the background of the MRSA strain COL and subsequent screening for a decreased level of methicillin resistance has identified several factors (fem or auxiliary genes) that, together with the mecA gene, are crucial for the expression of high-level and homogeneous resistance to methicillin (Step 11, see Figure 3). Although having a substantial impact on oxacillin resistance, these genes are not directly implicated in the expression of mecA, but they are mainly involved in cell wall metabolism and stress response. However, these studies were performed in a single MRSA strain (COL) and these same genes appear to have different contributions to β-lactams resistance in other S. aureus genetic backgrounds, suggesting that expression of β-lactam resistance is extremely complex and that auxiliary genes in different MRSA strains might be different or use different mechanisms. Additionally, whether the identified auxiliary genes in COL also contribute to β-lactam resistance expression in other Staphylococcus species is unknown.

What appears to hold true is that not all S. aureus appear to have the same ability to accommodate mecA. The existence of a host barrier was evidenced by the finding that SCCmec was acquired by a limited number of S. aureus genetic backgrounds (e.g., ST239, ST45, ST22, ST8, ST5) while other genetic backgrounds despite being successful, like ST121, were rarely observed carrying mecA. Furthermore, when a recombinant plasmid, carrying intact mecA, was introduced into strains that have never experienced the presence of mecA, they were unable to maintain or express β-lactam resistance, a phenomena not observed when the same assay was performed in MSSA strains from which SCCmec has been excised. Interestingly, either the presence of β-lactamase (blaR1-blaI) or mecA regulatory genes (mecR1-mecI), which control mecA expression, allowed the maintenance and expression of plasmid-carried mecA in the naïve genetic background, which is indicative that besides the genetic backgrounds the repression of mecA was important for the acquisition and stability of mecA in staphylococci. Actually, the so-called pre-MRSA although carrying mecA, showed a susceptible phenotype, which was shown to result from mecI-mediated repression of mecA transcription (Step 9, Figure 3). The integration of newly acquired genes into the recipient metabolic network is a complex mechanism that frequently represents a large fitness cost for bacteria. The presence of the regulators will probably work as safeguard mechanisms that will silence the newly acquired gene and avoid potentially harmful consequences of its expression in the new bacterial host, while it is still not adapted.

A different phenomenon supporting the importance of genetic background for the expression of β-lactam resistance is the emergence of the so-called oxacillin susceptible MRSA (OS-MRSA) (Step 9, Figure 3), strains that like pre-MRSA carry mecA and do not express β-lactam resistance, but that in contrast do not carry mecI (SCCmec IV or V). OS-MRSA have been recently described as a cause of infections in humans and have been also isolated from animals. Functional and genomic analysis of OS-MRSA and MRSA strains identified mutations in femA, a known auxiliary gene, as the possible cause of the observed decreased resistance to β-lactams. Although being described many years after the emergence of pre-MRSA, the exact date of OS-MRSA emergence is uncertain. Actually, since for several decades detection of MRSA in many hospitals was based in purely phenotypic approaches, OS-MRSA may have passed unnoticed. It could be that OS-MRSA correspond to strains that have recently acquired mecA and that have developed alternative mechanisms to compensate for the cost of acquisition of an exogenous gene.

Altogether, data suggest that for acquiring and maintaining mecA, S. aureus strains had to adapt its genetic background, compensated for mecA/SCCmec fitness cost, or were already intrinsically equipped for it. Still it remains to be clarified which genetic determinants and mechanism are involved in this adaptation process.

Homogeneous and Heterogeneous Expression of Resistance to Methicillin

The genetic alterations in genetic backgrounds and associated metabolic alterations described above to have occurred upon SCCmec acquisition were frequently paralleled by alterations in the cell population profile of β-lactam resistance expression. Clinical MRSA isolates, when cultured, frequently exhibit a low level of methicillin resistance, but contain subpopulations of bacteria displaying very high levels of resistance to this antibiotic, a feature called heterogeneous resistance (Step 10, Figure 3). Exposure of the hetero-MRSA strains to β-lactam antibiotics originates mutant strains in which all cells are uniformly highly resistant to β-lactams, named homogeneous methicillin resistance (Step 11, Figure 3). Both hetero and homo resistance phenotypes can be found in clinical MRSA isolates, but they appear to correspond to two different and sequential evolutionary stages of β-lactams resistance expression. However, the molecular basis of the emergence of heterogeneous resistance and of the heterogeneous-to-homogeneous conversion is not totally understood and appears to derive by multiple different mechanism, of which only a few have yet been identified.

Genetic analysis of colonies within the highly resistant subpopulation of a heteregeneous MRSA strains, showed that high resistance was associated to the deletion of lytH, encoding a putative lytic enzyme homologous to a N-acetylmuramyl-L-alanine amidase. But other mutations have been identified to provide the same type of phenotype, like mutations in mecI or in its promoter. More recently, the comparison of the whole genome of strains selected from high and low level resistant subpopulations identified, in highly resistant strains, two additional mutations in relA, which is involved in the synthesis of (p)ppGppas, an effector of the stringent stress response to many environmental and genetic changes.

and first hypothesized that the heterogeneous-to-homogeneous conversion of methicillin resistance results from a spontaneous chromosomal mutation that is not linked to mecA. showed by in vitro trans-complementation studies that hmrA and hmrB, which encode a putative aminohydrolase and an acyl carrier protein, respectively, were responsible for the conversion of the heterogenous profile (eagle type) of the N315 pre-MRSA strain into a uniformly highly resistant MRSA strain. Almost 20 years later a study wherein the whole genome of hetero-MRSA strain (N315) and its derivative homogeneously resistant strain selected by imipenem exposure, were compared confirmed that they differed in a single non-synonymous mutation in rpoB, encoding the RNA polymerase β subunit. Furthermore more recently, WGS revealed that tandem amplification of the SCCmec near its integration site was another alternative mechanism driving the heterogenous-to-homogeneous conversion.

Concluding Remarks

The development of mecA-mediated resistance to β-lactams was induced by human use of β-lactam antibiotics both to treat human infections and feed additives and involved several key genetic events: (1) the evolution of a native gene into a resistance determinant occurring at the native location; (2) the evolution of the SCC elements occurring at the orfX region; (3) integration of the mec complex and neighboring regions into a SCC element; (4) the adaptation of the host bacteria genetic background; (5) dissemination of SCCmec among staphylococci colonizing animals; (6) dissemination of SCCmec among staphylococci colonizing both animals and humans. Strikingly, most of the events that lead to β-lactam resistance development have occurred within the group of the most primitive animal-related Staphylococcus species isolated from production animals or human infection, suggesting it was a bacterial survival strategy against the human use of antimicrobials. The jump of SCCmec from animal to human-associated Staphylococcus species, like S. aureus, was a key event leading to several worldwide pandemics.

Author Contributions

The author confirms being the sole contributor of this work and has approved it for publication.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 140

  1. 1.

    Aiba Y. Katayama Y. Hishinuma T. Murakami-Kuroda H. Cui L. Hiramatsu K. (2013 ). Mutation of RNA polymerase beta-subunit gene promotes heterogeneous-to-homogeneous conversion of beta-lactam resistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57 4861–4871.

    Not in our library10.1128/aac.00720-13

  2. 2.

    Aminov R. (2017 ). History of antimicrobial drug discovery: major classes and health impact. Biochem. Pharmacol. 133 4–19.

    Not in our library10.1016/j.bcp.2016.10.001

  3. 3.

    Andrade-Figueiredo M. Leal-Balbino T. C. (2016 ). Clonal diversity and epidemiological characteristics of Staphylococcus aureus: high prevalence of oxacillin-susceptible mecA-positive Staphylococcus aureus (OS-MRSA) associated with clinical isolates in Brazil. BMC Microbiol. 16:115.

    Not in our library10.1186/s12866-016-0733-4

  4. 4.

    Antignac A. Tomasz A. (2009 ). Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene. Antimicrob. Agents Chemother. 53 435–441.

    Not in our library10.1128/aac.01099-08

  5. 5.

    Archer G. L. Niemeyer D. M. (1994 ). Origin and evolution of DNA associated with resistance to methicillin in staphylococci. Trends Microbiol. 2 343–347.

    Not in our library10.1016/0966-842x(94)90608-4

  6. 6.
  7. 7.
  8. 8.

    Baba T. Kuwahara-Arai K. Uchiyama I. Takeuchi F. Ito T. Hiramatsu K. (2009 ). Complete genome sequence of Macrococcus caseolyticus strain JCSCS5402, [corrected] reflecting the ancestral genome of the human-pathogenic staphylococci. J. Bacteriol. 191 1180–1190.

    Not in our library10.1128/jb.01058-08

  9. 9.

    Baig S. Johannesen T. B. Overballe-Petersen S. Larsen J. Larsen A. R. Stegger M. (2018 ). Novel SCCmec type XIII (9A) identified in an ST152 methicillin-resistant Staphylococcus aureus. Infect. Genet. Evol. 61 74–76.

    Not in our library10.1016/j.meegid.2018.03.013

  10. 10.

    Barber M. Rozwadowska-Dowzenko M. (1948 ). Infection by penicillin-resistant staphylococci. Lancet 2 641–644.

    Not in our library10.1016/s0140-6736(48)92166-7

  11. 11.

    Becker K. Ballhausen B. Kock R. Kriegeskorte A. (2014 ). Methicillin resistance in Staphylococcus isolates: the “mec alphabet” with specific consideration of mecC, a mec homolog associated with zoonotic S. aureus lineages. Int. J. Med. Microbiol. 304 794–804.

    Not in our library10.1016/j.ijmm.2014.06.007

  12. 12.
  13. 13.

    Berger-Bachi B. Rohrer S. (2002 ). Factors influencing methicillin resistance in staphylococci. Arch. Microbiol. 178 165–171.

    Not in our library10.1007/s00203-002-0436-0

  14. 14.

    Berglund C. Ito T. Ikeda M. Ma X. X. Soderquist B. Hiramatsu K. (2008 ). Novel type of staphylococcal cassette chromosome mec in a methicillin-resistant Staphylococcus aureus strain isolated in Sweden. Antimicrob. Agents Chemother. 52 3512–3516.

    Not in our library10.1128/aac.00087-08

  15. 15.

    Bouchami O. Ben Hassen A. de Lencastre H. Miragaia M. (2010 ). High prevalence of mec complex C and ccrC is independent of SCCmec type V in Staphylococcus haemolyticus. Eur. J. Clin. Microbiol. Infect. Dis. 31 605–614.

    Not in our library10.1007/s10096-011-1354-3

  16. 16.

    Bouchami O. Ben Hassen A. de Lencastre H. Miragaia M. (2012 ). Molecular epidemiology of methicillin-resistant Staphylococcus hominis (MRSHo): low clonality and reservoirs of SCCmec structural elements. PLoS One 6:e21940.

    Not in our library10.1371/journal.pone.0021940

  17. 17.

    Boundy S. Safo M. K. Wang L. Musayev F. N. O’Farrell H. C. Rife J. P. (2013 ). Characterization of the Staphylococcus aureus rRNA methyltransferase encoded by orfX, the gene containing the staphylococcal chromosome Cassette mec (SCCmec) insertion site. J. Biol. Chem. 288 132–140.

    Not in our library10.1074/jbc.m112.385138

  18. 18.

    Calazans-Silva A. C. Medeiros P. T. Araujo D. M. Carvalho B. O. Coelho I. S. Coelho S. M. (2014 ). Genetic analysis of mecA gene and detection of homologue pbpD in Staphylococcus sciuri group. Braz. J. Microbiol. 45 651–655.

    Not in our library10.1590/s1517-83822014000200038

  19. 19.

    Castanon J. I. (2007 ). History of the use of antibiotic as growth promoters in European poultry feeds. Poult. Sci. 86 2466–2471.

    Not in our library10.3382/ps.2007-00249

  20. 20.

    Chambers H. F. Deleo F. R. (2009 ). Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7 629–641.

    Not in our library10.1038/nrmicro2200

  21. 21.

    Chlebowicz M. A. Maslanova I. Kuntova L. Grundmann H. Pantucek R. Doskar J. (2014 ). The Staphylococcal Cassette Chromosome mec type V from Staphylococcus aureus ST398 is packaged into bacteriophage capsids. Int. J. Med. Microbiol. 304 764–774.

    Not in our library10.1016/j.ijmm.2014.05.010

  22. 22.

    Chongtrakool P. Ito T. Ma X. X. Kondo Y. Trakulsomboon S. Tiensasitorn C. (2006 ). Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements. Antimicrob. Agents Chemother. 50 1001–1012.

    Not in our library10.1128/aac.50.3.1001-1012.2006

  23. 23.

    Cohen S. Sweeney H. M. (1970 ). Transduction of methicillin resistance in Staphylococcus aureus dependent on an unusual specificity of the recipient strain. J. Bacteriol. 104 1158–1167.

    Not in our library10.1128/jb.104.3.1158-1167.1970

  24. 24.

    Continuous Discharge Certificate [CDC] (1999 ). Four pediatric deaths from community-acquired methicillin resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR 48 707–710.

    Not in our library

  25. 25.

    Couto I. de Lencastre H. Severina E. Kloos W. Webster J. A. Hubner R. J. (1996 ). Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri. Microb. Drug Resist. 2 377–391.

    Not in our library10.1089/mdr.1996.2.377

  26. 26.

    Couto I. Wu S. W. Tomasz A. de Lencastre H. (2003 ). Development of methicillin resistance in clinical isolates of Staphylococcus sciuri by transcriptional activation of the mecA homologue native to s. J. Bacteriol. 185 645–653.

    Not in our library10.1128/jb.185.2.645-653.2003

  27. 27.

    Crossley K. B. Archer G. L. (1997 ). The Staphylococci in Human Disease. London: Churchill Livingstone.

    Not in our library

  28. 28.

    de Lencastre H. Tomasz A. (1994 ). Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 38 2590–2598.

    Not in our library10.1128/aac.38.11.2590

  29. 29.

    Deurenberg R. H. Stobberingh E. E. (2008 ). The evolution of Staphylococcus aureus. Infect. Genet. Evol. 8 747–763.

    Not in our library10.1016/j.meegid.2008.07.007

  30. 30.

    Deurenberg R. H. Stobberingh E. E. (2009 ). The molecular evolution of hospital- and community-associated methicillin-resistant Staphylococcus aureus. Curr. Mol. Med. 9 100–115.

    Not in our library10.2174/156652409787581637

  31. 31.

    Diep B. A. Stone G. G. Basuino L. Graber C. J. Miller A. des Etages S. A. (2008 ). The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 197 1523–1530.

    Not in our library10.1086/587907

  32. 32.

    Ender M. McCallum N. Adhikari R. Berger-Bachi B. (2004 ). Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob. Agents Chemother. 48 2295–2297.

    Not in our library10.1128/aac.48.6.2295-2297.2004

  33. 33.

    Entenza J. M. Hohl P. Heinze-Krauss I. Glauser M. P. Moreillon P. (2002 ). BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46 171–177.

    Not in our library10.1128/aac.46.1.171-177.2002

  34. 34.

    European Union [EU] (2003 ). REGULATION (EC) No 1831/2003 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on additives for use in animal nutrition. Off. J. Eur. Union. L 268/29 1–30. (accessed Dec 30, 2005).

    Not in our library

  35. 35.

    Figueiredo T. A. Ludovice A. M. Sobral R. G. (2014 ). Contribution of peptidoglycan amidation to beta-lactam and lysozyme resistance in different genetic lineages of Staphylococcus aureus. Microb. Drug Resist. 20 238–249.

    Not in our library10.1089/mdr.2014.0042

  36. 36.

    Fleming A. (1929 ). Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. Rev. Infect. Dis. 2 129–139.

    Not in our library10.1093/clinids/2.1.129

  37. 37.

    Fluit A. C. (2012 ). Livestock-associated Staphylococcus aureus. Clin. Microbiol. Infect. 18 735–744.

    Not in our library10.1111/j.1469-0691.2012.03846.x

  38. 38.

    Food and Drug Administration [FDA] (2018 ). Antimicrobial Resistance. Avilable at: http://www.fda.gov/animalveterinary/safetyhealth/antimicrobialresistance/default.htm

    Not in our library

  39. 39.

    Fuda C. Suvorov M. Vakulenko S. B. Mobashery S. (2004 ). The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 279 40802–40806.

    Not in our library10.1074/jbc.m403589200

  40. 40.

    Fujimura T. Murakami K. (1997 ). Increase of methicillin resistance in Staphylococcus aureus caused by deletion of a gene whose product is homologous to lytic enzymes. J. Bacteriol. 179 6294–6301.

    Not in our library10.1128/jb.179.20.6294-6301.1997

All 140 references

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.